| WHAT IS K NOWN AND OBJEC TIVE
Lung cancer is one of the most common malignant tumours, with the second highest incidence rate among all tumours. It is also the leading cause of cancer-related deaths in both sexes.
1 Approximately 80% of lung cancers are non-small-cell lung cancers (NSCLC). Over 50% of patients with NSCLC have advanced local invasion and metastasis and, therefore, lose the opportunity for surgery. Hence, systemic chemotherapy or radiotherapy is often the primary choice. However, these therapies are often limited by their acute/subacute toxicity, which results in poor prognosis and quality of life (QOL). [2] [3] [4] Therefore, novel treatment strategies with higher levels of safety are urgently needed.
Cantharis has been used as anticancer drug in China for many years. Cantharidin is one compound, and terpenoid is extracted from cantharis, which is highly toxic in nature. 5, 6 Cantharidin derivatives, such as cantharidinate, norcantharidin, sodium demethylcantharidate and methyl-cantharidinimide, have strong antitumour activity, with low toxicity. In vitro, cantharidin derivatives show strong cytotoxic activity for a broad range of tumour cell lines by inducing cells' apoptosis. [7] [8] [9] [10] [11] In clinical practice, as an important cantharidin derivative, disodium cantharidinate with or without vitamin B6 has been widely used for lung cancer in China. [12] [13] [14] [15] Can sodium cantharidinate plus chemotherapy improve clinical efficacy with low toxicity in NSCLC? A previous meta-analysis [16] [17] [18] reported that compared with chemotherapy alone, sodium cantharidinate and vitamin B6 could improve tumour response, with a low risk of neutropenia and gastrointestinal toxicity. Another meta-analysis 19 reported that sodium cantharidinate with and without vitamin B6 could also improve tumour responses, with a low risk of neutropenia, but not a low risk of gastrointestinal toxicity. The results revealed that sodium cantharidinate could improve tumour responses. However, it is unclear whether sodium cantharidinate improves long-term survival rates. Except for strong cytotoxic activity for tumour cells, cantharidin derivatives may also be toxic to normal cells. Can sodium cantharidinate damage important organs, such as the heart, liver and kidney? What dosage is optimal for producing the desired efficacy and safety of treatment? Unfortunately, previous meta-analysis has not revealed these problems. The treatment's long-term survival rates, safety level and optimal dosage are unclear. There is a lack of ideal evidence to further validate these findings. As more new studies [20] [21] [22] [23] are published, we are here to systematically re-evaluate all related studies to reveal whether sodium cantharidinate improves clinical effectiveness in NSCLC.
| MATERIAL S AND ME THODS
This article followed Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines. Ethical approval was not required, as our study was a meta-analysis of published or ongoing studies.
| Inclusion and exclusion criteria
The following inclusion criteria were applied. The patients were diagnosed with NSCLC using histopathological and cytological diagnostic criteria, without surgical operations. The study design was randomized controlled trial (RCT). The interventions were sodium cantharidinate and vitamin B6 injection (Aiyishu injection) and cantharidinate injection. Sodium cantharidinate was intravenously injected, but not through intra-arterial or intrapleural infusion. The experimental group received sodium cantharidinate plus chemotherapy, and the control group received chemotherapy alone or plus placebo. Before being included in the study, the patients were not treated with radiotherapy and other Chinese herbs. There was no severe damage to the heart, liver or kidney function in any 
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clinical efficacy, meta-analysis, non-small-cell lung cancer, randomized controlled trial, sodium cantharidinate, systematic review patients. Clinical efficacy was evaluated through using tumour responses, QOL and long-term survival rate, and safety level was evaluated through using acute/subacute toxicity. There was no restriction on follow-ups and types of medical institutions.
The following exclusion criteria were applied: duplicates, animal and in vitro studies, studies about other types of tumours, studies about patients receiving radiotherapy, cantharidinate alone or other
Chinese herbs, and studies about other irrelevant themes, case reports and case-control studies (CCSs), meeting abstracts and reviews without specific data, irrelevant systematic reviews and metaanalyses, and studies without objective response rate (ORR) and disease control rate (DCR), QOL, long-term survival rates and acute or subacute toxicity. implemented using MeSH and free word, without language restrictions. Finally, all related systematic reviews (SRs) or meta-analysis were identified, and studies meeting the inclusion criteria were selected from the references.
| Search strategy

| Study selection
Two investigators (Shanshan Hu and Zhouke Tan) independently selected and evaluated the records, according to the inclusion and exclusion criteria. Any disagreements were resolved by discussion between themselves or with Zheng Xiao.
| Risk of bias assessment
Two investigators (Minghua Zhou and Zhouke Tan) subjectively reviewed all the trials and assigned a value of "high," "low" or "unclear" 
| Characteristics of the included trials
Thirty-eight trials involving 2845 patients with NSCLC were included in this meta-analysis (Table 1) Read the abstract and excluded reviews (n = 4), patent (n = 5), generic (n = 3), meeting summaries without specific data (n = 1); in vitro (n = 22), animal studies (n = 3); studies about surgical patients (n = 2), demethylcantharidate (n = 9), cantharidinate alone (n = 3), cantharidinate plus radiotherapy (n = 5), other tumors (n = 20); cantharidinate with intra-pleural injection (n = 3); other irrelevant themes (n = 16). docetaxel and cisplatin (DP), docetaxel and carboplatin (DC), docetaxel and nedaplatin (DN), and pemetrexed and cisplatin (PP 31 One trial 51 implemented the allocation concealment using envelope, and the other 37 trials did not provide detailed information regarding how the allocation concealment was implemented.
The blinding of the participants, personnel and outcome assessment was unclear in all trials. All trials had complete follow-ups. Four trials 23, 30, 48, 51 failed to completely report the acute/subacute toxicity.
Other bias was unclear. In all, 38 trials had at least three domains judged as unclear risk of bias, four trials 23, 30, 48, 51 had one domain considered as high risk of bias, and no trial had a low risk of bias (Figure 2 ). (Figures 3 and 4) . Figure 5 ).
| Tumour responses
| Quality of life
| Overall survival rate
Five trials 31, 39, 46, 51, 60 with 320 cases reported the 1-year OS rate, and one trial with 28 cases reported the 2-year OS rate ( Figure 6 ). Pearson's chi-square test and I 2 test showed that there Patients, non-small-cell lung cancer (NSCLC); E/C, experimental group (sodium cantharidinate plus chemotherapy)/control group (chemotherapy alone); M/F, male/female; Usage*, dose/times/Cycle; EP, etoposide and cisplatin; NP, navelbine and cisplatin; GP, gemcitabine and cisplatin; TP, paclitaxel and cisplatin; DN, docetaxel and nedaplatin; DC, docetaxel and carboplatin; GC, gemcitabine and carboplatin; DP, docetaxel and cisplatin; PP, pemetrexed and cisplatin; Scale A, evaluation criteria of tumour response; Scale B, evaluation criteria of acute/chronic toxicity; RECIST, response evaluation criteria in solid tumours; CTCAE, Common Terminology Criteria for Adverse Events; O, outcomes; O1, clinical response including the objective response rate (ORR) and disease control rate (DCR); O2, quality of life (QOL);
O3, overall survival (1-and 2-year OS rate); O4, acute/subacute toxicity; -, unclear.
TA B L E 1 (Continued) was no statistical heterogeneity among the trials (I 2 = 0%) in 1-year OS rate. The results showed that there were no significant differ- (Table 2 and Figure S6 ).
| Acute or subacute toxicity
| Subgroup analysis
To reveal the influence of sodium cantharidinate, with or without vita- (Table 3 and Figures S7-S8 ). The chemotherapy regimens included EP, NP, GP, GC, TP, DP, DC, DN and PP. Except for EP and PP, the subgroup analysis showed that other regimens could all increase the ORR and DCR (Table 3 and Figures S9-S10 ). Tumour responses were evaluated using WHO Criteria or RECIST. Subgroup analysis showed that sodium cantharidinate could increase the ORR and DCR using the WHO Criteria or RECIST (Table 3 and Figures S11-S12 ).
| Publication bias analysis
Funnel plots were symmetrical in ORR ( Figure 7A ). There was no publication bias in these trials that objectively reported the results. Funnel plots were significantly asymmetrical in DCR, QOL, neutropenia, thrombocytopenia, gastrointestinal reactions, and nausea and vomiting ( Figure 7B -G). They showed publication bias. The DCR was underestimated 43 and overestimated 22 in one trial, respectively. QOL was underestimated in one trial. 45 The gastrointestinal reactions were underestimated 36 and overestimated 33 in one trial, respectively. Neutropenia, thrombocytopenia or nausea and vomiting were overestimated.
| Sensitivity analysis
Four poor-quality trials 23, 30, 48, 51 failed to completely report the acute/subacute toxicity, which had selective reporting and potential effect on neutropenia, thrombocytopenia and nausea and vomiting (Table 4a) . Therefore, the sensitivity was evaluated by excluding the poor-quality trials. The results before and after excluding the poorquality studies had good stability. There was significant statistical heterogeneity for neutropenia, thrombocytopenia, gastrointestinal reaction, and nausea/vomiting, and minimal heterogeneity in QOL and DCR. All had publication bias. Therefore, the sensitivity was evaluated through excluding the trials with overestimated clinical efficacy or underestimated toxicity. The results before and after excluding the over-or underestimated studies had good stability (Table 4b ). In all, the stability was good in this meta-analysis.
| D ISCUSS I ON
Based on previous meta-analysis, [16] [17] [18] [19] twenty-two trials were added.
Finally, we included 38 trials involving 2845 patients with NSCLC 
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The analysis of 1-and 2-year OS rate between the two groups improve the QOL. There were sufficient studies and sample sizes for ORR, DCR and QOL. However, most trials had unclear bias risk. The ORR was objectively reported. The DCR was underestimated and overestimated, respectively. QOL was underestimated. Sensitivity analysis showed that results had good robustness. In all, we believe that sodium cantharidinate can improve the tumour responses and QOL in patients with NSCLC. Compared to previous studies, [16] [17] [18] [19] this meta-analysis further confirmed that sodium cantharidinate, Thus, we believe that sodium cantharidinate plus chemotherapy has a lower risk of haematotoxicity and gastrointestinal toxicity than chemotherapy alone. Moreover, it may not increase the risk of heart, liver and kidney toxicity. These findings need to be confirmed by new evidence. 
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